The discussion extendsto the importance for tumor-selective AMPK targeting, limitationsof cancer models for AMPK modulator evaluation, and the selectionof combination therapies, all factors for consideration in futureAMPK modulator development for anticancer treatment. This evidence concerns the gene PRKAB1 and cancer.